Filing Details

Accession Number:
0001012975-14-000649
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-10-02 17:43:07
Reporting Period:
2014-09-30
Filing Date:
2014-10-02
Accepted Time:
2014-10-02 17:43:07
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1293971 Bluebird Bio Inc. BLUE Biological Products, (No Disgnostic Substances) (2836) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1229592 Steven Gillis C/O Arch Venture Partners
8725 West Higgins Road, Suite 290
Chicago IL 60631
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2014-09-30 32,095 $36.08 1,272,616 No 4 S Indirect By ARCH Venture Fund VII, L.P.
Common Stock Disposition 2014-10-01 11,516 $34.75 1,261,100 No 4 S Indirect By ARCH Venture Fund VII, L.P.
Common Stock Disposition 2014-10-02 47,554 $34.87 1,213,546 No 4 S Indirect By ARCH Venture Fund VII, L.P.
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect By ARCH Venture Fund VII, L.P.
No 4 S Indirect By ARCH Venture Fund VII, L.P.
No 4 S Indirect By ARCH Venture Fund VII, L.P.
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.315, inclusive. The reporting person undertakes to provide to BLUE, any security holder of BLUE, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), and (3) to this Form 4.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.75 to $34.795, inclusive.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.75 to $35.03, inclusive.
  4. These shares are owned directly by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"). The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"). The Managing Directors of ARCH VII LLC, Robert T. Nelsen, Keith Crandell and Clinton Bybee, are deemed to have voting and dispositive power over the shares and may be deemed to beneficially own Fund shares held by ARCH Fund VII. Each Managing Director disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that such Managing Directors are the beneficial owners of such securities for Section 16 or any other purpose.
  5. Steven Gillis owns an interest in ARCH Partners VII but does not have voting or investment control over the shares held by ARCH Fund VII and disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that Steven Gillis is the beneficial owner of such securities for Section 16 or any other purpose.